Advertisement


Keith McCrae, MD, on Caplacizumab in Thrombotic Thrombocytopenic Purpura

2014 ASH Annual Meeting

Advertisement

Keith McCrae, MD, of the Cleveland Clinic, offers his thoughts on abstract 229, “Caplacizumab, Anti-Vwf Nanobody Potentially Changing the Treatment Paradigm in Thrombotic Thrombocytopenic Purpura: Results of the TITAN Trial,” presented by Flora Peyvandi, MD.



Related Videos

Lymphoma

Laurie Sehn, MD, on Nivolumab in Patients With Relapsed/Refractory Hodgkin Lymphoma

Laurie Sehn, MD, of the BC Cancer Agency, on abstract 289, “Nivolumab in Patients With Relapsed...

Lymphoma

Julie M. Vose, MD, MBA, FASCO, on the AETHERA trial

Julie M. Vose, MD, MBA, FASCO, of the University of Nebraska Medical Center, offers her thoughts on abstract 673,

Lymphoma

Laurie Sehn, MD, on Brentuximab Vedotin in Diffuse Large B-Cell Lymphoma With Undetectable CD30

Laurie Sehn, MD, of the BC Cancer Agency, on abstract 629, “Brentuximab Vedotin Monotherapy in ...

Leukemia

Linda J. Burns, MD, on CAR T-Cell Therapy in ALL

2014 ASH President Linda J. Burns, MD, of the University of Minnesota, offers her thoughts on abstract 380,

Lymphoma

Bertrand Coiffier, MD, PhD, on the Phase III LyMa Trial

Bertrand Coiffier, MD, PhD, of Centre Hospitalier Lyon-Sud, offers his thoughts on abstract 146, “


Advertisement



;
Advertisement